ParkinsonFranceV1, PubMed, Corpus, bibRecord, 001802

Electrophysiological effects of intravenous rilmenidine in man.

Identifieur interne : 001802 ( PubMed/Corpus ); précédent : 001801; suivant : 001803

Electrophysiological effects of intravenous rilmenidine in man.

Auteurs : J. Tonet ; C. Guillet ; G. Jondeau ; F. Poulain ; P. Vivet ; R. Frank ; Y. Grosgogeat

Source :

European journal of clinical pharmacology [ 0031-6970 ] ; 1991.

RBID : pubmed:1815965

English descriptors

KwdEn :
- Administration, Oral, Adult, Aged, Electrocardiography (drug effects), Electrophysiology, Female, Heart Conduction System (drug effects), Humans, Infusions, Intravenous, Male, Middle Aged, Oxazoles (administration & dosage), Oxazoles (blood), Oxazoles (pharmacology), Wolff-Parkinson-White Syndrome (physiopathology).
MESH :
- chemical , administration & dosage : Oxazoles.
- chemical , blood : Oxazoles.
- drug effects : Electrocardiography, Heart Conduction System.
- chemical , pharmacology : Oxazoles.
- physiopathology : Wolff-Parkinson-White Syndrome.
- Administration, Oral, Adult, Aged, Electrophysiology, Female, Humans, Infusions, Intravenous, Male, Middle Aged.

Abstract

Ten patients (44 y), 6 with the Wolff-Parkinson-White syndrome, and none with hypertensive disease, underwent electrophysiological studies before and after intravenous infusion of a single dose of 1 mg rilmenidine administered over 15 min. The regimen produced a mean plasma rilmenidine concentration of 3.16 ng.ml-1 at the end of the infusion. There was no significant change in sinus cycle length, PR interval, QRS, QT duration or in PA, AH and HV intervals. Estimated sinoatrial conduction time and corrected sinus node recovery time did not significantly change. In one patient, however, an abnormal pause was noted after termination of rapid atrial pacing. The right atrial effective refractory period decreased from 209 to 194 ms. There was no significant change in the anterograde and retrograde block cycle length or in the refractoriness of the nodal, ventricular and accessory pathways. The cycle length of induced reciprocating tachycardia decreased slightly from 374 to 351 ms. No patient exhibited an abnormal response to the carotid sinus massage. The findings indicate that intravenous administration of 1 mg rilmenidine exerts modest effects on the electrophysiological parameters of the human heart.

DOI: 10.1007/BF00314981
PubMed: 1815965

Links to Exploration step

pubmed:1815965

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Electrophysiological effects of intravenous rilmenidine in man.</title>
<author><name sortKey="Tonet, J" sort="Tonet, J" uniqKey="Tonet J" first="J" last="Tonet">J. Tonet</name>
<affiliation><nlm:affiliation>Hôpital Jean Rostand, Centre de Rythmologie et de Stimulation Cardiaque, Ivry, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Guillet, C" sort="Guillet, C" uniqKey="Guillet C" first="C" last="Guillet">C. Guillet</name>
</author>
<author><name sortKey="Jondeau, G" sort="Jondeau, G" uniqKey="Jondeau G" first="G" last="Jondeau">G. Jondeau</name>
</author>
<author><name sortKey="Poulain, F" sort="Poulain, F" uniqKey="Poulain F" first="F" last="Poulain">F. Poulain</name>
</author>
<author><name sortKey="Vivet, P" sort="Vivet, P" uniqKey="Vivet P" first="P" last="Vivet">P. Vivet</name>
</author>
<author><name sortKey="Frank, R" sort="Frank, R" uniqKey="Frank R" first="R" last="Frank">R. Frank</name>
</author>
<author><name sortKey="Grosgogeat, Y" sort="Grosgogeat, Y" uniqKey="Grosgogeat Y" first="Y" last="Grosgogeat">Y. Grosgogeat</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1991">1991</date>
<idno type="RBID">pubmed:1815965</idno>
<idno type="pmid">1815965</idno>
<idno type="doi">10.1007/BF00314981</idno>
<idno type="wicri:Area/PubMed/Corpus">001802</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001802</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Electrophysiological effects of intravenous rilmenidine in man.</title>
<author><name sortKey="Tonet, J" sort="Tonet, J" uniqKey="Tonet J" first="J" last="Tonet">J. Tonet</name>
<affiliation><nlm:affiliation>Hôpital Jean Rostand, Centre de Rythmologie et de Stimulation Cardiaque, Ivry, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Guillet, C" sort="Guillet, C" uniqKey="Guillet C" first="C" last="Guillet">C. Guillet</name>
</author>
<author><name sortKey="Jondeau, G" sort="Jondeau, G" uniqKey="Jondeau G" first="G" last="Jondeau">G. Jondeau</name>
</author>
<author><name sortKey="Poulain, F" sort="Poulain, F" uniqKey="Poulain F" first="F" last="Poulain">F. Poulain</name>
</author>
<author><name sortKey="Vivet, P" sort="Vivet, P" uniqKey="Vivet P" first="P" last="Vivet">P. Vivet</name>
</author>
<author><name sortKey="Frank, R" sort="Frank, R" uniqKey="Frank R" first="R" last="Frank">R. Frank</name>
</author>
<author><name sortKey="Grosgogeat, Y" sort="Grosgogeat, Y" uniqKey="Grosgogeat Y" first="Y" last="Grosgogeat">Y. Grosgogeat</name>
</author>
</analytic>
<series><title level="j">European journal of clinical pharmacology</title>
<idno type="ISSN">0031-6970</idno>
<imprint><date when="1991" type="published">1991</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Electrocardiography (drug effects)</term>
<term>Electrophysiology</term>
<term>Female</term>
<term>Heart Conduction System (drug effects)</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Oxazoles (administration & dosage)</term>
<term>Oxazoles (blood)</term>
<term>Oxazoles (pharmacology)</term>
<term>Wolff-Parkinson-White Syndrome (physiopathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Oxazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Oxazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electrocardiography</term>
<term>Heart Conduction System</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oxazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Electrophysiology</term>
<term>Female</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Ten patients (44 y), 6 with the Wolff-Parkinson-White syndrome, and none with hypertensive disease, underwent electrophysiological studies before and after intravenous infusion of a single dose of 1 mg rilmenidine administered over 15 min. The regimen produced a mean plasma rilmenidine concentration of 3.16 ng.ml-1 at the end of the infusion. There was no significant change in sinus cycle length, PR interval, QRS, QT duration or in PA, AH and HV intervals. Estimated sinoatrial conduction time and corrected sinus node recovery time did not significantly change. In one patient, however, an abnormal pause was noted after termination of rapid atrial pacing. The right atrial effective refractory period decreased from 209 to 194 ms. There was no significant change in the anterograde and retrograde block cycle length or in the refractoriness of the nodal, ventricular and accessory pathways. The cycle length of induced reciprocating tachycardia decreased slightly from 374 to 351 ms. No patient exhibited an abnormal response to the carotid sinus massage. The findings indicate that intravenous administration of 1 mg rilmenidine exerts modest effects on the electrophysiological parameters of the human heart.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1815965</PMID>
<DateCreated><Year>1992</Year>
<Month>06</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted><Year>1992</Year>
<Month>06</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0031-6970</ISSN>
<JournalIssue CitedMedium="Print"><Volume>41</Volume>
<Issue>6</Issue>
<PubDate><Year>1991</Year>
</PubDate>
</JournalIssue>
<Title>European journal of clinical pharmacology</Title>
<ISOAbbreviation>Eur. J. Clin. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Electrophysiological effects of intravenous rilmenidine in man.</ArticleTitle>
<Pagination><MedlinePgn>537-40</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Ten patients (44 y), 6 with the Wolff-Parkinson-White syndrome, and none with hypertensive disease, underwent electrophysiological studies before and after intravenous infusion of a single dose of 1 mg rilmenidine administered over 15 min. The regimen produced a mean plasma rilmenidine concentration of 3.16 ng.ml-1 at the end of the infusion. There was no significant change in sinus cycle length, PR interval, QRS, QT duration or in PA, AH and HV intervals. Estimated sinoatrial conduction time and corrected sinus node recovery time did not significantly change. In one patient, however, an abnormal pause was noted after termination of rapid atrial pacing. The right atrial effective refractory period decreased from 209 to 194 ms. There was no significant change in the anterograde and retrograde block cycle length or in the refractoriness of the nodal, ventricular and accessory pathways. The cycle length of induced reciprocating tachycardia decreased slightly from 374 to 351 ms. No patient exhibited an abnormal response to the carotid sinus massage. The findings indicate that intravenous administration of 1 mg rilmenidine exerts modest effects on the electrophysiological parameters of the human heart.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tonet</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Hôpital Jean Rostand, Centre de Rythmologie et de Stimulation Cardiaque, Ivry, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Guillet</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jondeau</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Poulain</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Vivet</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Frank</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Grosgogeat</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Eur J Clin Pharmacol</MedlineTA>
<NlmUniqueID>1256165</NlmUniqueID>
<ISSNLinking>0031-6970</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>P67IM25ID8</RegistryNumber>
<NameOfSubstance UI="C032302">rilmenidine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006329" MajorTopicYN="N">Heart Conduction System</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010080" MajorTopicYN="N">Oxazoles</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014927" MajorTopicYN="N">Wolff-Parkinson-White Syndrome</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1991</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1991</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">1815965</ArticleId>
<ArticleId IdType="doi">10.1007/BF00314981</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001802 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001802 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:1815965
   |texte=   Electrophysiological effects of intravenous rilmenidine in man.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:1815965" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Electrophysiological effects of intravenous rilmenidine in man.

Electrophysiological effects of intravenous rilmenidine in man.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki